Integrated Symposium:
Tackling the global epidemic of MDR Gram-negative bacteria: the evolving role of novel β-lactam/β-lactamase inhibitor combinations

ESCMID appointed chair: Souha S. Kanj, Beirut, Lebanon
Industry chair: Roman S. Kozlov, Smolensk, Russian Federation

Global epidemic of Gram-negative resistance, economic burden and unmet needs; global initiatives to address antimicrobial resistance
John H. Rex, Boston, MA, United States

Challenges to adequate initial therapy and identification of risk factors for complicated infections: why, when and who to treat
Antoni Torres, Barcelona, Spain

Innovative approaches to β-lactamase inhibition
Peter M. Hawkey, Birmingham, United Kingdom

Clinical focus on emerging β-lactam/β-lactamase inhibitor combinations for the treatment of complicated infections caused by MDR Gram-negative bacteria
Florian M.B. Wagenlehner, Giessen, Germany

Organized by: AstraZeneca